Epitalon Longevity Protocol

Published Epitalon research by Khavinson and colleagues has used doses of 0.1–1 mg/kg in animal studies and 0.1–10 µg/mL in cell culture experiments. Early clinical investigations used 5–10 mg administered via injection over 10–20 consecutive days per cycle.

All figures are drawn from published research and are provided for research reference only.

The published Epitalon research uses a cyclical administration pattern: 10–20 consecutive days of administration followed by an extended rest period (typically 4–6 months) before the next cycle. This cycle reflects the observed duration of telomerase activation and melatonin normalisation effects in animal models. Multiple annual cycles have been studied in longevity research.

Researchers monitoring Epitalon longevity protocols have measured: telomere length (qPCR or FISH-based methods); TERT (telomerase reverse transcriptase) expression via RT-PCR; melatonin levels (serum or urinary 6-OHMS); oxidative stress markers (8-OHdG, F2-isoprostanes, MDA); and circadian rhythm markers (cortisol rhythm, temperature rhythm). In animal lifespan studies: overall survival curves, tumour incidence, and organ histology at endpoint.

Epitalon has an excellent safety profile across 40+ years of published research from the Khavinson group. No significant adverse effects have been reported at research doses in animal or early human studies. The p53-independent mechanism of telomerase activation is of theoretical safety interest (telomerase activation is associated with cancer in other contexts) but no increased tumour incidence has been observed; in fact, reduced tumour incidence has been reported in some animal longevity studies.

Protocol Overview

This protocol outlines research parameters for Epitalon telomere biology and longevity investigations, drawn from the published Khavinson and Anisimov research series.

Research goal: Longevity — telomere extension, melatonin restoration, antioxidant pathway Primary peptide: Epitalon (Ala-Glu-Asp-Gly) Duration: 10–20 day active cycles, repeated 2–3 times per year Model systems: Human fetal fibroblast culture, lymphocyte cultures, rodent lifespan studies, early clinical observations

Scientific Context

Epitalon is the only peptide in the research literature with documented telomerase activation in normal somatic cells via a p53-independent pathway (Khavinson et al., 2003, PMID: 12665553). The cyclical administration pattern reflects the finding that a single treatment course produces telomerase activation that persists for several months in cell culture models before returning to baseline.

Secondary research endpoints — melatonin restoration and antioxidant pathway activation — align with Epitalon's pineal gland origin: it is a synthetic analog of the pineal extract Epithalamin and directly stimulates pinealocyte melatonin synthesis.

Biological Rationale for Cyclical Dosing

Telomerase activity in treated cells follows a bell-curve time course: activation peaks within days of treatment, is sustained for weeks, then gradually returns to baseline. This kinetic profile supports cyclical (rather than continuous) administration in research designs aimed at episodic telomere maintenance.

Referenced Research

• [Khavinson 2003 — Epitalon Telomerase Activation](/research/khavinson-2002-epitalon-telomerase)
• Epitalon Monograph

Research Use Only · Not for human consumption · Consult a qualified researcher or physician before any protocol.